Filtrar

Publicações

Real World Data On Multiple Myeloma In Brazil: Patterns Of Care In The Private Healthcare System

Abstract

Multiple Myeloma (MM) is a rare malignancy, accounting for only 0.8% of all cancers and 10% of hematologic malignancies in the world.
The main goals of MM treatment are to destroy malignant plasma cells; prevent or relieve symptoms; improve patient´s life quality; and increase patient´s overall survival (1, 2). ...

Patterns of care and burden of chronic idiopathic thrombocytopenic purpura in Brazil

Abstract

Although several therapeutic options are available for chronic immune thrombocytopenic purpura (cITP), little is known about the treatment of cITP in Brazil. Materials and methods: A multi-center, retrospective chart review, observational study was designed to describe the treatment patterns, clinical burden, resources use, ...

Oncologic pain: attitudes, intensity and treatment in Brazil

Abstract

Pain is an important and highly prevalent symptom among oncology patients, affecting more than 50% of them. Patient reported outcomes (PRO) data are essential to decision-making process, especially with regard to medical symptoms. The biomedical community seldom investigates oncologic pain within the context of its ...

Multiple myeloma patients’ profiles and regimens transitions in the Brazilian private healthcare sector

Abstract

Multiple Myeloma (MM) is a rare hematologic disease that is increasing 0.8% each year. Recently, due to the development of novel medicines, death rates are decreasing 0.8% each year(1). MM prognosis has substantially improved after the use of these novel medicines, such as proteasome inhibitors (PI), immunomodulators ...

Patient and tumor profiles in the Brazilian private setting: data from the AUDITRON claims database

Abstract

Scientific progress in oncology led to development of new tools for diagnosis and novel therapies resulting in survival gain for several neoplasms and increased costs related to disease management. Therefore, increased cancer management-related cost has been a new concern for patients, health care providers, and society ...

Pink October in the social media: are we still (mis)guiding the public?

Abstract

Breast cancer is the most frequent cancer among women both in the developed and in the developing world. GLOBOCAN estimated 1.67 million new cases of the disease in 2012, with over 522,000 deaths worldwide.1 In Brazil, the National Cancer Institute (INCA) estimated 57,960 new cancer cases in 2016, with over 14,000 ...

Use of brentuximab vedotin to treat Hodgkin lymphoma in a private sector setting in Brazil

Abstract

Hodgkin Lymphoma (HL) is a blood cell tumor that accounts for less than 1% of all cancers occurring annually in the world (1, 2). Incidence estimates for Brazil in 2016 were 2,470 new cases of the disease, 59.1% men (3). Treatment for early stages of HL consists in two to four cycles of combined chemotherapy (usually ...

Real world data on multiple myeloma treatment patterns: first and second-line treatment in the Brazilian public health system

Abstract

The healthcare information data system SIASUS (Sistema de Informações Ambulatoriais do SUS) is a publicly available database established in 1992, which supports the funding for ambulatory services in the Brazilian Public Healthcare System. (1) Since 1997, SIASUS processes all APAC formularies (Autorização de ...

Bevacizumab for breast cancer: scientific evidence versus real world data (rwd) in Brazil

Abstract

Breast cancer (BC) is considered the most common type of cancer among women in the world and also in Brazil (excluding non-melanoma skin cancer), accounting for about 28% of new cases each year. It can also affect men, although it is rare, representing only 1% of the total cases of the disease. Relatively uncommon before age ...

Unrecommended oncologic treatments: how much do they cost and how can we prevent resource waste?

Abstract

Scientific progress has led to the development and approval of new antineoplastic drugs on the market, increasing the hope of cancer patients, but bringing with it escalating costs. The World Cancer Report from 2014 issued by the International Agency for Research on Cancer (IARC) and the World Health Organization (WHO) ...